About Genovis

Genovis’ business concept is to offer customers in the pharmaceutical and medical device industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Today Genovis sells several enzyme products known as SmartEnzymes all over the world in innovative product formats that facilitate development and quality control of biological drugs.

An important cornerstone of Genovis’ R&D activities is customer relations that enables product development to meet customer needs. Just as valuable is the collaboration with academic groups that focus on characterizing new enzymes.

The Group consists of Genovis AB, Sweden, and the wholly owned subsidiary Genovis Inc., USA. The company has aprox. 2,600 shareholders and the company's shares are listed on Nasdaq First North Growth Market. Find more information at Investor Relations